Compare Citius Pharmaceuticals Inc (CTXR) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Occidental Petroleum Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Occidental Petroleum Corporation trades at $54.5 (market cap $54.28B). The key difference: Occidental Petroleum Corporation is far larger — about 3707.7× Citius Pharmaceuticals Inc's market cap, and Occidental Petroleum Corporation pays a 1.91% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | OXY | |
|---|---|---|
Market Cap | $14.64M | $54.28B |
Sector | Health | Energy |
52-Week High | $1.82 | $66.24 |
52-Week Low | $0.53 | $38.92 |
Enterprise Value | $10.86M | $75.36B |
Dividend Yield | — | 1.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Occidental Petroleum (OXY) trades at $54.81, up 3.63% with bullish technical signals and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust profitability with 22.42% net income margin and 14.04% ROE, though revenue has declined from $36.6B in 2022 to $21.6B in 2025. Analyst consensus is positive with 50% buy ratings and $66.14 price target, while recent news highlights operational improvements and geopolitical tailwinds from higher oil prices.
OXY presents a compelling investment case with earnings outperformance, debt reduction progress, and favorable oil price environment, but faces risks from commodity volatility and execution challenges in carbon capture initiatives. The stock's current valuation at 74x P/E requires sustained earnings growth to justify further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
